Comparative Efficacy of Chinese Patent Medicines for Coronary Heart Disease and Diabetes

Dan Han's dataset contains results from a network meta-analysis of 71 randomized controlled trials involving 7,988 patients. It compares the efficacy and safety of 14 oral Chinese patent medicines combined with conventional therapy for coronary heart disease complicated by diabetes. The data was last updated on April 30, 2026.

Use Cases

• Ranking treatment efficacy for specific outcomes like glycemic control and lipid profiles based on the network meta-analysis results.
• Identifying which oral Chinese patent medicine is associated with the best improvement in cardiac function parameters such as LVEF and LVESD.
• Comparing the safety profiles of different adjunctive therapies based on reported adverse reactions and MACE incidence.
• Analyzing the impact of combined therapies on inflammatory markers like IL-6, TNF-α, and hs-CRP.

Strengths

• Includes data from 71 randomized controlled trials, providing a substantial evidence base.
• Covers a total sample size of 7,988 patients.
• Evaluates a wide range of clinical outcomes including glycemic control, lipid profiles, cardiac function, and inflammatory markers.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small at 149.0 KB, indicating limited raw data or a summary table.

Provenance

Source

figshare, author Dan Han

Collection Method

Systematic review and network meta-analysis of randomized controlled trials from Chinese and international databases.

Freshness

Last updated 2026-04-30 04:18:12; freshness should be verified.

Geography

Likely focuses on trials conducted in China, given the subject matter.